Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis

Nature Medicine

Volumn 1, Issue 5, 1995, Pages 442-447

  Gottlieb, Scott L ^a   Gilleaudeau, Patricia ^a   Johnson, Ray ^a   Estes, Len ^b   Woodworth, Thasia G ^b   Gottlieb, Alice B ^a   Krueger, James G ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b Seragen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD8 ANTIGEN; DENILEUKIN DIFTITOX;

ADULT; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; KERATINOCYTE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIASIS; T LYMPHOCYTE ACTIVATION;

ADULT; CELL DIFFERENTIATION; CELL MOVEMENT; CELLS, CULTURED; DIPHTHERIA TOXIN; EPIDERMIS; FEMALE; HUMAN; IMMUNOTOXINS; INTERLEUKIN-2; KERATINOCYTES; MALE; PSORIASIS; RECOMBINANT FUSION PROTEINS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; T-LYMPHOCYTES;

EID: 0028990380     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm0595-442     Document Type: Article

References (36)

1. Weinstein, G. D. & Krueger, J. G. An overview of psoriasis, in Therapy of Moderate-to-Severe Psoriasis (eds Weinstein, G.D. & Gottlieb, A.B.) 1-22 (National Psoriasis Foundation, Portland, Oregon 1993).
2. Vallat, V. P. et al. PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: A possible cellular basis for remittive therapy, J. exp. Med. 180, 283-296 (1994).
3. Bos, J.D. et al. Predominance of "memory" T cells (CÐ4+, CDw29+) over "naive" T cells (CD4+, CD45R+) in both normal and diseased human skin. Arch, dermatol. Res. 281, 24-30 (1989).
4. Gottlieb, A. B. et al. Expression of HLA-DR molecules by keratinocytes and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques. J. exp. Med. 164, 1013-1028 (1986).
5. Gottlieb, A. B., Chang, C. K., Posnett, D. N., Fanelli, B. & Tam, J. P. Detection of transforming growth factor alpha in normal, malignant, and hyper-proliferative human keratinocytesJ. exp. Med. 167, 670-675 (1988).
6. Elder, J. T. et al. Overexpression of transforming growth factor alpha in psoriatic epidermis. Science 243, 811-814 (1989).
7. Nickoloff, B. J. & Naidu, Y. Perturbation of epidermal barrier function correlates with initiation of cytokine cascade in human skin. J. Am. Acad. Dermatol. 30, 535-546 (1994).
8. Henseler, T. & Christophers, E. Psoriasis of early and late onset: Characterization of two types of psoriasis vulgaris. J. Am. Acad. Dermatol 13, 450-456 (1985)
9. Baadsgaard, O., Fisher, G., Voorhees, J. J. & Cooper, K. D. The role of the immune system in the pathogenesis of psoriasis. J. invest. Dermatol 95, 32S-34S (1990).
10. Chang, J. C. C. et al. CD8+ T cells in psoriatic lesions preferentially use T-cell receptor Vß3 and/or Vßl3.1 genes. Proc. natn. Acad. Sci. U.S.A. 91, 9282-9286 (1994).
11. Gottlieb, A. B. & Krueger, J. G. Role of T-lymphocytes (in psoriasis pathogenesis) in Psoriasis (ed. Dubertret, L.) 63-71 (ISED Publishing Co, Brescia, Italy, 1994)
12. Prinz, J. C. et al. T cell clones from psoriasis skin lesions can promote ker-atinocyte proliferation in vitro via secreted products. Eur. J. Immun. 24, 593-598 (1994).
13. Bata-Csorgo, Z., Hammerberg, C., Voorhees, J. J. & Cooper, K. D. Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. J. clin. Invest 95, 317-327 (1995).
14. Krueger, J. G. & Gottlieb, A. B. Growth factors, cytokines and eicosanoids (in psoriasis pathogenesis) in Psoriasis (ed. Dubertret, L.) 18-28 (ISED Publishing Co., Brescia, Italy, 1994)
15. Baker, B. S. et al. The effects of cyclosporin A on T lymphocyte and dendritic cell sub-populations in psoriasis. Br. J. Dennatol. 116, 503-510 (1987).
16. Rizova, H. et al. The effect of anti-CD4 monoclonal antibody treatment on immunological changes in psoriatic skin. J. dermatol Sci. 7, 1-13 (1994).
17. Ackerman, C. et al. Recalcitrant psoriasis and pyoderma gangrenosum treated with FK506. J. invest Dermatol 96, 536 (1991).
18. Petzelbauer, P., Stingl, G., Wolff, K. & Volc-Platzer, B, Cyclosporin A suppresses ICAM-1 expression by papillary endothelium in healing psoriatic plaques. J. invest Dermatol. 96, 362-369 (1991).
19. Gottlieb, A. B. et al. Studies of the effect of cyclosporine in psoriasis in vivo: Combined effects on activated T lymphocytes and epidermal regenerative maturation. J. invest Dermatol. 98, 302-309 (1992).
20. Khandke, L. et al. Cyclosporine in psoriasis treatment: Inhibition of keratinocyte cell-cycle progression in G1 independent of effects on transforming growth factor-alpha/epidermal growth factor receptor pathways. Arch. Dermatol. 127, 1172-1179 (1991).
21. Williams, D. P. et al. Diphtheria toxin receptor binding domain substitution with interleukin-2: Genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Protein Engng 1, 493-498 (1987).
22. Waters, C A. et al. Interleukin 2 receptor-targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin-related interleukin 2 fusion protein into cells. Eur. f. Immun. 20, 785-791 (1990).
23. Waldman, T. A. The IL-2/IL-2 receptor system: a target for rational immune intervention. Immun. Today 14, 264-270 (1993).
24. 3g9EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins. J. biol Chem. 266, 21118-21124(1991).
25. Mansbridge, J. N. & Knapp, A.M. Changes in keratinocyte maturation during wound healing. J. invest Dermatol. 89, 253-263 (1987).
26. Valdimarsson, H., Baker, B. S., Jonsdottir, I., Powles, A. & Fry, L. Psoriasis: A T-cell-mediated autoimmune disease induced by streptococcal superantigens? Immun. Today 16, 145-149 (1995).
27. Paukkonen, K., Naukkarinen, A. & Horsmanheimo, M. The development of manifest psoriatic lesions in linked with the invasion of CD8+ T cells and CDllc+ macrophages into the epidermis. Arch. Dermatol. Res. 284, 375-379 (1992).
28. Onuma, A. Immunohistochemical studies of infiltrating cells in early and chronic lesions of psoriasis. J. Dermatol. 21, 223-232 (1994)
29. Gottlieb, S.L. et al. Short-contact anthralxn treatment augments therapeutic efficacy of cyclosporine in psoriasis. A clinical and pathologic study. J. Am. Acad. Dermatol (in the press).
30. Hammer, R. E., Maika, S. D., Richardson, J. A., Tang, J.P. & Taurog. J. D. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta2m: An animal model of HLA-B27-associated human disorders. Cell 63, 1099-1112 (1990).
31. Carnaud, C. & Bach, J-F. Cellular basis of T-cell autoreactivity in autoimmune diseases. Immun. Res. 12, 131-148 (1993).
32. Bacha, P.L. et al. Impact of interleukin-2-receptor-targeted cytotoxins on a unique model of murine interleukin-2-receptor-expressing malignancy. Int. J. Cancer 49, 96-101(1991).
33. Krane, J. F. et al. Increased dermal expression of platelet-derived growth factor receptors in growth-activated skin wounds and psoriasis. J. invest Dermatol 96, 983-986 (1991).
34. Tomfohrde, J. et al. Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science 264, 1141-1145 (1994).
35. 486IL-2) in hematologic malignancies expressing the IL-2 receptor. Blood 79, 2547-2554(1992).
36. Fredriksson, T. & Pettersson, U. Severe psoriasis-oral therapy with a new retinoid, Dermatologica 157, 238-244 (1978).